NEW YORK (GenomeWeb) – Karius, a three-year-old startup with a commercial test to diagnose infectious diseases by sequencing cell-free pathogen DNA in blood, is beginning to narrow its focus on the most promising immediate applications for its assay.
Karius Eyeing Sepsis, Transplant Patients as Key Markets for Infectious Disease Sequencing Test
Premium
Get the full story with
360Dx Premium
Only $95 for the
first 90 days*
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.